Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclaris Therapeutics, Inc. (ACRS) SEC filings page on Stock Titan provides access to the company’s public filings with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other key documents referenced in its investor communications. Aclaris is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
For ACRS, SEC filings are an important source of information on financial results, clinical development progress, and corporate presentations. Recent Forms 8-K have furnished press releases announcing quarterly and year-to-date financial results, described as including revenue from contract research and licensing, research and development expenses tied to product candidates such as bosakitug, ATI-052 and ATI-2138, and general and administrative costs. Other 8-K filings have furnished R&D Day and corporate overview presentations and detailed top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis.
Through this page, users can locate Aclaris’ current reports that summarize material events, such as updates to its clinical pipeline, conference calls discussing top line clinical data, and investor presentations. While the examples provided are 8-K filings, the SEC Filings page is also the natural place to look for Aclaris’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and any proxy statements or registration statements the company files, which together outline its risk factors, business description, and governance structure.
Stock Titan enhances these filings with AI-powered tools that can help explain complex financial and scientific disclosures in plain language. For ACRS, this can be particularly useful when reviewing detailed discussions of its immuno-inflammatory pipeline, revenue components such as licensing and contract research, and non-cash items like royalty income and contingent consideration revaluations. The page also provides a path to monitor any future insider transaction reports on Form 4 or other ownership-related filings that may be associated with Aclaris’ executive officers and directors.
Aclaris Therapeutics’ Chief Business Officer James Loerop received new equity awards dated February 2, 2026. He was granted 97,700 restricted stock units, each representing one future share of common stock, and 341,900 employee stock options with a $3.61 exercise price.
The RSUs vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on continued service. The stock options also vest in four equal annual installments over the same schedule, becoming exercisable as service-based vesting conditions are met.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported new equity awards. On February 2, 2026, he received 99,100 restricted stock units, each representing one share of Aclaris common stock. These RSUs vest in four equal annual installments starting on the first anniversary of February 2, 2026, conditioned on his continued service.
He was also granted an employee stock option for 346,800 shares of common stock at an exercise price of $3.61 per share. The option becomes exercisable as 25% of the shares vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported routine equity compensation activity. On February 3, 2026, 20,875 restricted stock units were converted into an equal number of Aclaris common shares. Each restricted stock unit represents the right to receive one share of common stock.
To cover tax withholding on this vesting, the issuer withheld 5,937 common shares at $3.47 per share, reported under transaction code F. After these transactions, Loerop directly owned 192,260 shares of common stock and 62,625 restricted stock units, which continue to vest in four equal installments on the first four anniversaries of February 3, 2025, subject to continuous service.
Aclaris Therapeutics CEO Walker Neal reported equity compensation activity involving restricted stock units and common stock. On February 3, 2026, 63,475 restricted stock units were converted into 63,475 shares of common stock at an exercise price of $0.
To cover tax withholding related to this vesting, 18,611 shares of common stock were withheld by the company at a price of $3.47 per share. After these transactions, Neal directly owned 1,543,886 shares of common stock and 190,425 restricted stock units, which vest in four equal annual installments starting on February 3, 2025, subject to continuous service.
Aclaris Therapeutics President and COO Hugh M. Davis reported an equity compensation transaction involving restricted stock units (RSUs). On February 3, 2026, 18,675 RSUs converted into 18,675 shares of Aclaris Therapeutics common stock at an exercise price of $0 per share.
After this transaction, Davis directly owned 45,425 shares of common stock and 56,025 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs underlying this transaction vest in four equal annual installments on the first through fourth anniversaries of February 3, 2025, subject to his continuous service.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity. On February 3, 2026, 22,025 restricted stock units converted into an equal number of common shares at an exercise price of $0. To cover tax withholding on this vesting, 6,449 common shares were withheld by the company at $3.47 per share.
After these transactions, Balthaser directly owned 185,755 shares of common stock and 66,075 restricted stock units, which continue to vest in four equal annual installments starting from February 3, 2025, contingent on his continued service.
Aclaris Therapeutics, Inc.'s Chief Business Officer reported multiple equity compensation events on February 1, 2026. Several restricted stock unit (RSU) awards were exercised (transaction code M), delivering 11,250, 7,500, and 14,750 shares of common stock in separate transactions.
The filing also reports a transaction coded F, where 10,686 shares were withheld at $3.51 per share to cover tax obligations tied to RSU vesting. The RSU grants vest in four equal annual installments starting on February 1 of 2022, 2023, and 2024, subject to continued service. This amendment corrects a prior filing that mistakenly referenced a February 1, 2025 transaction due to a filing platform error.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity involving restricted stock units and common stock. On February 1, 2026, 14,750 restricted stock units were converted into an equal number of shares of Aclaris common stock, reflecting previously granted equity awards.
To cover related tax withholding on this vesting, the issuer withheld 4,984 shares of common stock at $3.51 per share. Following these transactions, Balthaser directly held 170,179 shares of common stock and 29,500 restricted stock units. The remaining restricted stock units vest in four equal annual installments beginning on the first anniversary of February 1, 2024, contingent on his continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported an automatic share withholding related to equity compensation. On February 1, 2025, the issuer withheld 15,980 shares of common stock at $2.48 per share to cover his tax obligations upon restricted stock unit vesting.
After this transaction, Loerop beneficially owned 102,773 shares of Aclaris common stock in direct ownership. The filing is an amendment that corrects the previously reported number of shares withheld, which will change the reported beneficial ownership amounts in later filings.
Aclaris Therapeutics’ chief business officer filed an amended insider share report to correct how many shares were withheld for taxes on vested restricted stock units. On 02/01/2025, the company withheld 15,980 shares of common stock at $2.48 per share to cover tax obligations. After this correction, the officer directly held 102,773 shares of Aclaris common stock. The amendment clarifies the prior disclosure and will adjust reported beneficial ownership in future filings.